ATE324435T1 - Virale zubereitungen, vektoren, immunogene und impfstoffe - Google Patents

Virale zubereitungen, vektoren, immunogene und impfstoffe

Info

Publication number
ATE324435T1
ATE324435T1 AT96903115T AT96903115T ATE324435T1 AT E324435 T1 ATE324435 T1 AT E324435T1 AT 96903115 T AT96903115 T AT 96903115T AT 96903115 T AT96903115 T AT 96903115T AT E324435 T1 ATE324435 T1 AT E324435T1
Authority
AT
Austria
Prior art keywords
virus
gene
immunomodulatory protein
site
genetic material
Prior art date
Application number
AT96903115T
Other languages
English (en)
Inventor
Stephen Charles Inglis
Michael Edward Griff Boursnell
Original Assignee
Cantab Pharmaceuticals Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9503395.7A external-priority patent/GB9503395D0/en
Priority claimed from GBGB9515557.8A external-priority patent/GB9515557D0/en
Priority claimed from GBGB9603322.0A external-priority patent/GB9603322D0/en
Application filed by Cantab Pharmaceuticals Res Ltd filed Critical Cantab Pharmaceuticals Res Ltd
Application granted granted Critical
Publication of ATE324435T1 publication Critical patent/ATE324435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96903115T 1995-02-21 1996-02-21 Virale zubereitungen, vektoren, immunogene und impfstoffe ATE324435T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9503395.7A GB9503395D0 (en) 1995-02-21 1995-02-21 Viral,preparations,immunogens,and vaccines
GBGB9515557.8A GB9515557D0 (en) 1995-07-28 1995-07-28 Viral preparation,immunogens and vacciness
GBGB9603322.0A GB9603322D0 (en) 1996-02-16 1996-02-16 Viral preparations,immunogens and vaccines

Publications (1)

Publication Number Publication Date
ATE324435T1 true ATE324435T1 (de) 2006-05-15

Family

ID=27267593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903115T ATE324435T1 (de) 1995-02-21 1996-02-21 Virale zubereitungen, vektoren, immunogene und impfstoffe

Country Status (9)

Country Link
US (4) US6287557B1 (de)
EP (2) EP1683858A3 (de)
JP (2) JPH11500014A (de)
AT (1) ATE324435T1 (de)
AU (1) AU711121B2 (de)
CA (1) CA2211743A1 (de)
DE (1) DE69636068T2 (de)
ES (1) ES2264136T3 (de)
WO (1) WO1996026267A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
AU5333298A (en) 1996-12-27 1998-07-31 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
GB9816761D0 (en) 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
GB9816775D0 (en) * 1998-07-31 1998-09-30 Efstathiou Stacey Herpesviral vectors for gene delivery
EP2272859B1 (de) * 1998-08-07 2014-10-22 University of Washington Immunologische Herpes-Simplex Antigene und Verfahren zu ihrer Verwendung
EP1038952A3 (de) * 1998-12-09 2001-06-27 Pfizer Products Inc. Verfahren zur Herstellung von Mareks Disease Virus (MDV) unter Verwendung von kontinuierlichen Vogelzellinien
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE60036105D1 (de) * 1999-06-08 2007-10-04 Uab Research Foundation Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
ATE312189T1 (de) * 2000-01-21 2005-12-15 Biovex Ltd Virusstämme für die onkolytische behandlung von krebs
GB0013817D0 (en) * 2000-06-06 2000-07-26 Univ Nottingham Trent Method for treating cells
WO2002036761A2 (en) 2000-11-03 2002-05-10 Dana Farber Cancer Institute Compositions and methods for the diagnosis of cancer
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
IL161251A0 (en) 2001-10-10 2004-09-27 Neose Technologies Inc Remodeling and glycoconjugation of peptides
SE0201701D0 (sv) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003295502A1 (en) 2002-11-12 2004-06-03 Yucheng Chang Adenoviral vector vaccine
JP2007535304A (ja) 2003-11-24 2007-12-06 シドニー キンメル キャンサー センター ムチン抗原ワクチン
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
EP2059255A4 (de) * 2006-09-08 2011-08-31 Univ Pennsylvania Hsv-1- und hsv-2-impfstoffe sowie verfahren zu ihrer anwendung
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2114449B1 (de) * 2006-12-28 2016-02-17 The Trustees of the University of Pennsylvania Kombinierte herpes simplex virus subunit-impfstoffe und anwendungsverfahren
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2011093858A1 (en) * 2010-01-27 2011-08-04 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
LT2569436T (lt) 2010-05-14 2018-03-12 Oregon Health & Science University Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
CA2904001C (en) 2013-03-05 2021-07-13 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
WO2016011293A1 (en) 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
CN108064304A (zh) 2015-02-10 2018-05-22 俄勒冈健康与科学大学 可用于产生非典型cd8+ t细胞应答的方法和组合物
EP3377636A4 (de) 2015-11-20 2019-11-06 Oregon Health & Science University Cmv-vektoren mit mikrorna-erkennungselementen
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
EP3624851A1 (de) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stabile virushaltige zusammensetzung
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1992005363A1 (en) * 1990-09-18 1992-04-02 Lucas Industries Public Limited Company Fuel injection nozzles
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
BR9106879A (pt) * 1990-09-25 1993-07-20 Cantab Pharma Res Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
HU218849B (hu) 1992-06-01 2000-12-28 American Cyanamid Co. Gazdaszervezetről gazdaszervezetre a környezetben csökkent terjedési képességgel rendelkező rekombináns bakulovirus és eljárás előállítására
AU4560693A (en) * 1992-07-30 1994-03-03 Akzo Nobel N.V. Non-shedding live herpesvirus vaccine
WO1994003207A1 (en) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
US20020009462A1 (en) * 1992-07-31 2002-01-24 David M. Knipe Herpesvirus replication defective mutants
US5658724A (en) * 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US5661033A (en) * 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
EP0689603A1 (de) * 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff
WO1994024296A2 (en) * 1993-04-19 1994-10-27 University Of Saskatchewan Recombinant bovine herpesvirus type 1 vaccines
WO1994029469A2 (en) * 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
WO1995003399A2 (en) 1993-07-19 1995-02-02 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
WO1995014091A2 (en) * 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions and methods for utilizing conditionally lethal genes
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
US5928913A (en) * 1995-03-23 1999-07-27 Efstathiou; Stacey Vectors for gene delivery
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system

Also Published As

Publication number Publication date
EP1683858A2 (de) 2006-07-26
JPH11500014A (ja) 1999-01-06
EP0811057A1 (de) 1997-12-10
ES2264136T3 (es) 2006-12-16
AU711121B2 (en) 1999-10-07
US20030091535A1 (en) 2003-05-15
US6287557B1 (en) 2001-09-11
EP1683858A3 (de) 2006-08-02
US20020150562A1 (en) 2002-10-17
EP0811057B1 (de) 2006-04-26
AU4726396A (en) 1996-09-11
JP2007130022A (ja) 2007-05-31
CA2211743A1 (en) 1996-08-29
DE69636068T2 (de) 2006-11-30
US20050118192A1 (en) 2005-06-02
DE69636068D1 (de) 2006-06-01
WO1996026267A1 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
DE69636068D1 (de) Virale zubereitungen, vektoren, immunogene und impfstoffe
JP3895366B2 (ja) ウィルス ワクチン
IL164318A0 (en) Recombinant mva virus and vaccine comprising said virus
EP0882134B1 (de) Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
ATE118822T1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
MY157873A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties